BioSpace News Archive

Drug Development

OSE Immunotherapeutics to Resume Accrual in Phase III Clinical Trial of Tedopi in Advanced Non-Small Cell Lung Cancer Patients Following Immune Checkpoint Inhibitor Treatment

There continue to be no safety concerns, as safety data remain similar to what was expected for Tedopi® based on the results of previous clinical trials.

December 7, 2017

·

6 min read

Business

Innate Pharma Announces Its Financial Calendar for 2018

All corporate information on the Company, such as its financial statements or its corporate presentations, is available on the Company’s website.

December 7, 2017

·

3 min read

Business

CohBar Announces the Appointment of Dr. John Amatruda to Its Board

Dr. Amatruda, a CohBar co-founder, has over 25 years of experience as a senior pharmaceutical research executive and scientific consultant, together with over 40 years of experience in the practice and teaching of medicine.

December 7, 2017

·

5 min read

Biotech Bay

Scientists From SRI International and Collaborations Pharma Identify Potential New Ebola Virus Therapy

The low molecular weight immunomodulatory drug has shown promising efficacy with 100 percent survival in an Ebola virus disease model.

December 7, 2017

·

3 min read

Drug Development

Adocia Announces Positive Topline Study Results Comparing Ultra-Rapid Insulin BioChaperone Lispro With Novolog and Fiasp in People With Type 1 Diabetes

This Phase 1 study in insulin pumps is the first head-to-head comparison of two “ultra-rapid acting” insulin formulations.

December 7, 2017

·

5 min read

Drug Development

GenSight Biologics Reports Positive Long-Term Visual Acuity Gains and Safety Results From Phase I/II Study of GS010 for the Treatment of Leber Hereditary Optic Neuropathy (LHON)

In the study, five cohorts of three subjects were administered an increasing dose of GS010 via a single intravitreal injection in the eye more severely affected by the disease.

December 7, 2017

·

8 min read

BioCapital

RegeneRx Biopharma Releases Annual Letter to Shareholders

The letter is focused on updating shareholders on the Company’s product development and commercial partnerships, clinical trials, fund-raising, and other operational plans over the next twelve months.

December 7, 2017

·

2 min read

Pharm Country

Novartis Initiates Study Evaluating Impact of Higher Dosing of Cosentyx in Patients With Ankylosing Spondylitis

The primary endpoint of ASLeap is to determine the difference between Cosentyx 300 mg and Cosentyx 150 mg at Week 52 based on the proportion of subjects achieving inactive disease status based on the ASDAS.

December 7, 2017

·

14 min read

Business

Champions Oncology Reports Record Quarterly Revenue of $5.2M

Champions Oncology today announced its financial results for the second fiscal quarter and six months ended October 31, 2017.

December 7, 2017

·

19 min read

Business

BioPharmX Reports Third Quarter 2018 Financial Results

Total operating expenses for the third quarter of 2018 were $3.7M, compared with total operating expenses of $4.2M in the prior fiscal year’s third quarter.

December 7, 2017

·

18 min read